Morphic Medical, Inc.

Morphic Medical, Inc. formerly known as GI Dynamics, and founded in 2003, dedicated to developing medical technologies for diabetes treatment. As of March 2026, Mike Gutteridge operates as CEO of the company. In February 2026, Morphic Medical, Inc.

raised USD 8 million in venture funding from Crystal Amber. Morphic Medical’s core product offering is the RESET® therapy, an innovative endoscopically delivered device designed to treat type 2 diabetes and obesity. This therapy aims to bridge the treatment gap for patients who are underserved by traditional pharmaceuticals or injections and for whom surgical options may not be viable. RESET works by targeting the underlying causes of type 2 diabetes, ultimately aiming to reduce HbA1c levels and assist in weight management.

The therapy is currently approved for sale in the European Union and is undergoing clinical trials in the United States, where the company is actively enrolling participants in the STEP-1 clinical study. Morphic Medical serves a diverse client base, including healthcare providers and patients in the U. S. and Europe, addressing a global need for effective diabetes treatment solutions amidst rising diabetes prevalence.

Morphic Medical's revenue model revolves around the commercialization of its RESET therapy through partnerships with healthcare providers and institutions. The company engages in direct transactions with hospitals and clinics that adopt their technology, facilitating the delivery of treatment to patients. These transactions encompass agreements for the purchase or lease of the device, with potential training and support services included as part of the initial engagement. The firm’s pricing strategy aligns with industry standards for medical devices focused on diabetes treatment, reflecting the value provided in terms of healthcare outcomes and patient management.

Given the innovative nature of RESET, the revenue structure may include opportunities for collaborative research partnerships aimed at further clinical validation and expansion of the therapy’s applications. In February 2026, Morphic Medical, Inc. raised USD 8 mn in venture funding from Crystal Amber to support ongoing clinical studies, regulatory progress, device deployment, and international distribution efforts. The company is focusing on expanding its RESET therapy into new markets, specifically targeting the United States as it continues its clinical trials.

Future plans include enhancing product capabilities based on trial outcomes and exploring additional international markets to accommodate rising diabetes prevalence.